Biolife Solutions Inc SEC Filings

BioLife Solutions Inc. executive files small preplanned stock sale. Chief Human Resources Officer Sarah Aebersold sold 219 shares of common stock on March 3, 2026 in an open-market transaction at $20.74 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted effective February 24, 2022 to satisfy tax withholding obligations from vested restricted stock. After this transaction, she directly holds 93,360 shares of BioLife Solutions common stock.

BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported an open-market sale of 353 shares of common stock at $20.74 per share on March 3, 2026. After this transaction, he directly held 165,940 shares of BioLife Solutions common stock.

According to the footnote, this sale was executed under a pre-established Rule 10b5-1(c) trading plan, adopted effective February 24, 2022. The plan was designed to satisfy tax withholding obligations related to the vesting of restricted stock, indicating the sale was part of a planned, tax-driven process rather than a discretionary trade.

KAREN FOSTER submitted a Form 144 notice for the proposed sale of 96,923 common shares of BLFS, to be effected on 03/05/2026 following the exercise of stock options and for cash. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker. The record also shows a prior sale by Ms. Foster of 335 common shares on 01/06/2026 for $8,572.65.

BioLife Solutions furnished an investor presentation outlining its position as a focused provider of biopreservation media and cell processing tools for cell-based therapies. For 2025, the company reports pro forma revenue of about $96 million, representing 29% organic growth after divesting storage, services and freezer businesses.

Adjusted EBITDA margin reached 26% in 2025, with adjusted EBITDA of roughly $25 million and gross margin around 65%, highlighting a shift to a higher-margin, consumables‑driven model. The materials state that BioLife products are specified in more than 70% of U.S. cell‑based therapy clinical trials and used in roughly 90% of commercially relevant FDA‑approved cell‑based therapies.

The presentation cites a cell‑based therapy market expected to grow over 20% annually through 2030 and a current addressable market of about $4 billion for BioLife’s offerings. Management is guiding to 17–20% revenue growth in 2026, with positive GAAP net income for the full year and continued adjusted EBITDA margin expansion.

BioLife Solutions Chief Marketing Officer Todd Berard reported equity compensation and related tax withholding in company stock. He received two grants of restricted common shares, one for 20,096 shares that vests 25% after one year and then in 12 quarterly installments, and another for 22,479 shares that vested at approximately 156% of the target grant based on the company’s total shareholder return versus selected peers from January 1, 2024 through December 31, 2025. In connection with the vesting of the market-based award, 8,846 shares were withheld at a price of $22.65 per share to cover tax obligations, leaving him with 166,293 common shares held directly after these transactions.

DuRoss Amy reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions director Amy DuRoss received an award of 8,170 shares of Common Stock as restricted stock. The grant was made at no cash cost under the BioLife Solutions 2023 Performance Incentive Plan and will fully vest on the first anniversary of the vesting date of January 2, 2026. After this award, DuRoss directly holds 26,857 common shares.

BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported equity compensation and related tax withholding transactions in company stock. On February 24, 2026, he acquired 31,150 shares and 64,866 shares of restricted common stock at $0 per share as grants under the 2023 Omnibus Performance Incentive Plan.

The first grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The second grant vested at approximately 156% of the target number of shares based on total shareholder return from January 1, 2024 through December 31, 2025 versus a peer group. To cover tax withholding on the vested market-based award, 25,525 shares were disposed of at $22.65 per share. Following these transactions, Wichterman directly held 221,237 shares of common stock.

Hunt Anthony reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions Inc. director Anthony Hunt received a grant of 8,170 shares of common stock as a restricted stock award. The award was made at no cash cost per share and increased his directly held common stock to 15,046 shares following the transaction. According to the footnote, the restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026."

Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.